The CSL offer is set at $273 ( or a 2% discount to the share price if CSL shares fall below this mark). Bids for the stock must be lodged by the 7th February, 2022. “The combination with Vifor Pharma is expected to be financially compelling for our shareholders while expanding and diversifying our revenue base.
What are the expenses of CSL Limited?
Selling and marketing expenses (51.8) (58.4) General and administration expenses (168.6) (147.3) Finance costs (27.4) (25.7) Profit before income tax expense 692.5 1,153.8 Income tax expense (0.1) (33.8) Profit for the year 692.4 1,120.0 50 Notes to the Financial Statements CSL Limited Balance Sheet 2019 US$m 2018 US$m
What is the financial performance of CSL?
The financial performance of CSL makes up the majority weighting of the KPIs for Executive KMP, incentivising the delivery of strong financial performance. In 2019, the financial performance measures were NPAT and CFO. NPAT at 30 June 2019 resulted in an above target performance, however CFO was below target (and above threshold). The remaining
